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Metastatic melanoma is notoriously one of the most difficult cancers to treat. Although many therapeutic
regimens have been tested, very few achieve response rates greater than 25%. Given the rising incidence of
melanoma and the paucity of effective treatments, there is much hope and excitement in leveraging recent
genetic and molecular insights for therapeutic advantage. Over the past 30 years, elegant studies by many
groups have helped decipher the complex genetic networks involved in melanoma proliferation, progression
and survival, as well as several genes involved in melanocyte development and survival. Many of these
oncogenic loci and pathways have become crucial targets for pharmacological development. In this article we
review: (1) our current understanding of melanoma genetics within the context of signaling networks; (2)
targeted therapies, including an extensive discussion of promising agents that act in the Bcl-2 signaling network;
(3) future areas of research.
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Introduction
For decades, cutaneous melanoma has
frustrated both clinicians and research-
ers alike. The incidence of melanoma
has been increasing at an alarming rate;
currently, the lifetime risk of develop-
ing melanoma is 1/58 for males in the
United States, but has been reported to
be as high as 1/25 for Australian males
(Jemal et al., 2008). Although melano-
ma is highly curable, there is currently
no effective treatment for metastatic
melanoma. Despite over 20 years of
trials with various therapeutic combi-
nations, dacarbazine (DTIC) and IL-2
remain the standard treatment for
advanced melanoma despite response
rates of only 15–25% (Tsao et al.,
2004a). A cure for advanced melanoma
thus remains a critical imperative both
at the benchside and at the bedside.
Over the past two-and-a-half dec-
ades, application of innovative meth-
odologies and technologies has helped
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Editor’s Note
Malignant melanoma remains one of the cancers most
resistant to treatment. Last month in the JID new approaches
to the pathogenesis of melanoma were reviewed, including
the possible role of stem cells and the use of animal models
to understand the pathogenesis of the disease. Over the last
decades rapid advances in our understanding of the genetics
of cancer and in the use of the immune system to treat
cancer have had a significant impact in both our under-
standing of the pathogenesis of cancer and in designing new
treatment protocols. In this issue of the JID, Hocker and
colleagues review the most recent advances in the genetics
of melanoma and how these findings relate to understanding
its pathogenesis and treatment. In the final article in this
Perspectives Series Fang and colleagues describe how recent
advances in immunotherapy have led to new treatment
strategies for this life threatening form of skin cancer. While
melanoma remains an enigma both in its pathogenesis and
its treatment, this Perspective series highlights several
promising areas of new investigation that hold great promise
for the development of successful treatments for this ’’most
interesting and complex problem of oncology‘‘ (James Ewing
(1930) The problems of melanoma. BJ Med 11:852–6).
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define melanoma as a highly complex,
yet potentially comprehensible, dis-
ease. Early identification of melanoma
oncogenes, such as NRAS, and mela-
noma tumor suppressor genes (TSGs),
such as CDKN2A, resulted from labor-
intensive approaches such as func-
tional and positional cloning. Starting
in the 1990s, a major technological
revolution fueled by the Human
Genome Project changed the land-
scape of cancer research. Platforms
such as high-throughput resequencing
and solid/liquid phase microarrays
have improved our understanding of
determinants of melanoma tumorigen-
esis, thereby setting the stage for more
efficacious therapies and more accu-
rate biomarkers. Genetically informed
targeted therapies have demonstrated
promising results in many early clinical
trials of patients with advanced mela-
noma. Similarly, attempts to arrive at a
molecular classification of melanoma
hold significant potential with regard to
diagnosis, prognosis, and appropriate
selection of therapeutic regimens.
Thus, increased insight into the genet-
ics of melanoma is essential for
continued progress in the accurate
diagnosis, prognosis, and treatment of
this notoriously intractable disease. In
this review, our aim is to provide a
framework that one can use to under-
stand the melanoma cell’s distinct, yet
highly interconnected genetic networks
and the ways that we can target them
therapeutically.
GENETICS OF MELANOMA:
DISRUPTION OF MULTIPLE
SIGNALING NETWORKS
In the past few decades, increases in our
understanding of the genetics of mela-
noma have led to a better understanding
of the molecular engine that drives
melanoma tumorigenesis and a more
promising future in terms of therapy. In
this section of the review, we will
discuss some of the major genes, path-
ways, and networks involved in mela-
noma tumorigenesis with an emphasis
on the elements that show the greatest
promise as possible therapeutic targets.
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Figure 1. Melanoma signaling networks. Shown is a simplified diagram of three of the major genetic networks involved in melanoma tumorigenesis, survival, and
senescence. Included in the NRAS signaling network (green) are the MAPK and the PI3 Kinase/AKT pathways, which have been implicated in melanoma
proliferation, survival, and progression. The CDKN2A locus encodes two separate tumor suppressors, p16 and p14ARF, both of which are thought to contribute to
senescence and tumor growth restriction. The p53/Bcl-2 signaling network (red) is a major contributor to melanoma apoptosis and chemosensitivity and is regulated
by many of the oncogenic melanoma pathways. Shown at the top of the figure are selected therapeutic agents that target each of these genetic networks.
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Throughout our discussion, we will
highlight the high degree of crosstalk
that occurs between the pathways that
regulate growth and apoptosis, as this
has ramifications for therapy.
Melanocyte and melanoblast prolif-
eration, survival, differentiation, and
migration are all critical elements of
normal developmental physiology. The
signaling circuitry that regulates these
events is often indelibly altered at the
genetic level by the aspiring melanoma
cell. Although a large number of genes
have been mutated in melanoma,
many of these loci are uniquely and
critically positioned within signaling
networks (Figure 1). It is thus more
instructive nowadays to think about
activated or abrogated pathways and
networks rather than individual onco-
genes and TSGs. In this regard, we will
focus on two large cancer circuits—the
growth-promoting Ras signaling net-
work, the tumor-constraining CDKN2A
network—and their interaction with a
key downstream regulator of apoptosis,
the Bcl-2/p53 network. We will also
touch on three melanocyte develop-
mental regulators that have emerged as
critical melanoma determinants.
The Ras signaling network: promoting
proliferation and progression
The complex Ras signaling network
regulates cell growth, survival, and
invasion through two distinct cas-
cades—the Ras/mitogen-activated pro-
tein kinase (MAPK) and the Ras/
phosphatidylinositol-3-kinase (PI3K) sig-
naling streams. The importance of the
Ras signaling network in melanoma
cannot be overstated: up to 90% of
melanomas and benign melanocytic
neoplasms carry activating mutations in
one of two key MAPK pathway genes,
BRAF or NRAS. Although less common,
melanomas lacking activating mutations
in NRAS or BRAF may in fact harbor
genetic alterations in other downstream
components of the MAPK pathway
(Curtin et al., 2005). Similarly, altera-
tions in the PI3K pathway have been
reported in up to 50–60% of melanomas
(Zhou et al., 2000; Stahl et al., 2004).
Although it may be convenient to
conceptualize the MAPK and PI3K path-
ways as being two completely indepen-
dent signaling cascades, there is in fact
significant crosstalk between these (and
other) intracellular signaling pathways.
Thus it is important to consider the
individual genetic alterations in these
two pathways in the larger context of the
Ras signaling network.
NRAS
Functional cloning studies in the early
1980s revealed Ras GTPases as onco-
proteins that were frequently mutated in
a large number of human cancers. In
1984, Albino et al. reported that DNA
from 4/30 melanoma cell lines yielded
transforming RAS genes in the NIH/3T3
assay thus establishing RAS as the first
oncogene in melanoma (Albino et al.,
1984). Notably, the alterations were
mainly in NRAS, a then lesser-known
isoform in the RAS family. Subsequent
studies have further substantiated RAS in
melanoma biology: (1) activating NRAS
mutations are relatively common (26%)
in sporadic melanoma (Hocker and Tsao,
2007), (2) oncogenic NRAS is capable of
inducing melanoma in CDKN2A-defi-
cient mice (Ackermann et al., 2005),
and (3) oncogenicHRAS has been shown
to play a key role in melanoma main-
tenance in murine models (Chin et al.,
1999). Although NRAS is now accepted
to be a key oncogene in human mela-
noma, other members of the RAS family
of proteins have a limited role in humans.
Among melanocytic tumors, HRAS al-
terations have been found in Spitz nevi
(Bastian et al., 2000b).
As Ras activates both the MAPK and
PI3K pathways, it is thought that
redundant downstream activating mu-
tations do not provide additional survi-
val benefits and may in fact be
cytotoxic (Petti et al., 2006). Indeed,
mutations in NRAS have been demon-
strated to occur in a reciprocal pattern
with genes downstream of it in either
pathway, such as PTEN and BRAF
(Tsao et al., 2004b; Curtin et al.,
2005). NRAS mutations have been
reported to be more frequent on
chronically sun-exposed sites (Jiveskog
et al., 1998). However, the most
common Gln61 alterations in NRAS
are not classic UVB-signature changes
(Hocker and Tsao, 2007) and NRAS
mutations appear to be at least as
common in congenital nevi as melano-
ma (Papp et al., 1999; Bauer et al.,
2007), indicating that sun exposure is
not necessary to induce the most
common NRAS mutations. These data
suggest that oncogenic NRAS, which
arises by a yet-to-be-determined mole-
cular mechanism(s), promotes melano-
cytic proliferation but is not sufficient
to yield true malignant transformation.
RAF-MAPK cascade: a major stimulus of
melanocytic proliferation
BRAF. Armed with technological tools
and readily available information de-
rived from the Human Genome Pro-
ject, it is now possible to resequence
large regions of the cancer genome. As
Ras signaling is ubiquitously activated
in many cancers and as its downstream
components are often protein kinases,
the Wellcome-Trust Sanger Institute’s
(www.sanger.ac.uk) cancer genome
project initiated an effort to resequence
all relevant human protein kinases (that
is, the kinome) in a large number of
cancers. One of the first and perhaps
most substantial findings was the dis-
covery of a highly recurrent mutation in
BRAF among different cancer types
including melanoma (Davies et al.,
2002). About 80% of the reported
changes occurred at a single codon in
the BRAF kinase domain (that is,
c.T1799A, p.Val600Glu). Although
BRAF was mutated in less than 20%
of most cancers, this gene was altered
in 80% of short-term melanoma cell
cultures and 66% of uncultured mela-
nomas thereby making BRAF the single
most commonly mutated gene in mel-
anoma. The discovery of a highly
recurrent mutation in BRAF launched
a new era in melanoma therapeutics
and provided validation of the high-
throughput resequencing strategy now
adopted by the National Cancer Insti-
tute’s Cancer Genome Project.
Mutagenic activation of the MAPK
pathway is observed in up to 90% of
melanomas and is most commonly
achieved via mutations in NRAS or
BRAF. Mutations in these two genes
occur in a mutually exclusive manner
(Pollock et al., 2003; Tsao et al., 2004b),
suggesting some degree of functional
redundancy between these genetic
events. Similar to oncogenic NRAS, the
BRAFT1799A mutation is prevalent in
benign nevi supporting a role for BRAF
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activation in melanocytic proliferation,
but not full transformation (Pollock et al.,
2003; Yazdi et al., 2003). This hypoth-
esis has been experimentally validated
using a zebrafish model, where it has
been shown that BRAF activation leads
only to development of benign nevi,
whereas progression to frank melanoma
requires concurrent p53 inactivation
(Patton et al., 2005). Furthermore, onco-
genic BRAF has been shown to result in
a senescence-like state, marked by
increased expression of senescence-
associated acidic b-galactosidase
(Michaloglou et al., 2005). Thus, the full
oncogenic potential of BRAF appears to
be dictated by the presence or absence
of other genetic constraints.
The precise carcinogenic mechanism
underlying the BRAFT1799A mutation re-
mains unclear. The T4A transversion is
not a classic UVB signature change and
many internal malignancies harbor the
identical BRAF alteration, thus UV radia-
tion is clearly not essential for c.T1799
mutagenesis. Moreover, the c.T1799A
mutation has been shown to occur most
frequently on tumors arising from inter-
mittently sun-exposed sites and not on
chronically sun-damaged skin, where
UVB exposure is most intense (Curtin
et al., 2005). Given these findings, it has
been suggested that UVB-induced cyclo-
butane pyrimidine dimer formation at the
neighboring position (c.1800–1801) may
promote subsequent BRAF mutations at
the 1799 position (Thomas et al., 2006).
More recently, Landi et al. (2006) re-
ported that BRAF mutations are more
common in individuals with MC1R
mutations suggesting that there may be
germline supervision of tumor somatic
alterations including the BRAFT1799A
change. Further insight into the mechan-
ism of BRAF mutagenesis may have
significant clinical implications and also
help explain why the rarer melanoma
subtypes (for example, acral lentiginous
and lentigo maligna melanoma) have a
low frequency of BRAFT1799A mutations
(Hocker and Tsao, 2007).
Investigators have also sought to
establish a correlation between BRAF
mutational status, disease progression,
and clinical outcome, but have failed
to consistently demonstrate a signifi-
cant association (Dong et al., 2003;
Kumar et al., 2003; Libra et al., 2005).
Thus, although much remains to be
understood regarding its exact role in
melanoma biology, BRAF is a key
element in melanoma tumorigenesis
and crucial therapeutic target.
PI3K-AKT cascade: promoter of
melanoma progression
As with the MAPK pathway, NRAS
plays a central role in increasing
signaling through this pathway. Once
activated, Ras induces the membrane
translocation and activation of PI3K.
PI3K phosphorylates phospatidylinosi-
tol-4,5-biphosphate to phospatidylino-
sitol-3,4,5-triphosphate, which leads to
activation of the pathway’s major
downstream effector, Akt. Downstream
effectors of Akt promote proliferation,
survival and invasion (Sharma et al.,
2005). Although activating mutations
in PI3K, itself, are believed to be rare,
other downstream components of the
PI3K pathway have been shown to be
altered in up to 50–60% of melanomas
(Zhou et al., 2000; Stahl et al., 2004).
Notably, although the data have been
mixed regarding a potential role for Ras-
MAPK pathway in melanoma progres-
sion, multiple studies have supported a
role for Ras-PI3K pathway activation in
disease progression. More specifically,
the expression of PI3K and AKT have
been shown to steadily increase during
the progression from benign nevi to early
melanoma, and lastly, to metastatic
disease (Dhawan et al., 2002; Stahl
et al., 2004; Aziz et al., 2007). Thus, it
is felt that concomitant inhibition of these
two signaling pathways will be necessary
to combat melanoma tumorigenesis and
progression. Indeed, it was recently
demonstrated that a number of metastatic
melanoma cell lines were resistant to
independent inhibition of the MAPK or
PI3K pathways but susceptible to simul-
taneous inhibition of these pathways,
with growth and invasion of being
blocked in vitro (Smalley et al., 2006).
PI3K. Aziz et al. (2007) recently used
an automated quantitative in situ ana-
lysis, in a large study comparing PI3K
protein expression in 548 melanomas
and 540 benign nevi. PI3K expression
was shown to be higher in melanomas
than in nevi, and was significantly
higher in metastatic specimens. High
expression levels also correlated with
Breslow thickness 42mm, absence of
tumor infiltrating lymphocytes, and
decreased survival. Activating muta-
tions in PI3K have been reported to
occur in only B1% of primary mela-
nomas (Curtin et al., 2006b), and
comparative genomic hybridization
data have yet to demonstrate amplifi-
cation of any PI3K subunit in primary
melanomas (Bastian et al., 1998; Curtin
et al., 2005). Nonetheless, PI3K protein
expression is frequently increased in
melanoma and thus may serve as a
potential therapeutic target.
PTEN. A key downstream component
of the PI3K pathway, PTEN (also
designated PTEN/MMAC1), is com-
monly altered in melanoma and is
thought to be one of the main media-
tors of PI3K pathway activation and
melanoma tumorigenesis. Early loss-of-
heterozygosity studies suggested the
presence of a chromosome 10q locus
lost early in tumor progression. PTEN
was one of the putative TSGs on
chromosome 10 and had been shown
to be mutated in gliomas, breast,
prostate, and kidney cancers and mel-
anomas (Steck et al., 1997). Tsao et al.
(1998b) screened 45 melanoma cell
lines and 17 paired uncultured meta-
static melanoma and found that
approximately 15% of the specimens
had some evidence of structural injury
to PTEN. Inactivating mutations in
PTEN and activating mutations in
NRAS were shown to exist in a
reciprocal fashion, suggesting that the
loss of PTEN and the activation of
NRAS may functionally overlap (Tsao
et al., 2000); moreover, ectopic expres-
sion of PTEN in several cutaneous
melanoma cell lines suppressed colony
formation irrespective of PTEN or
NRAS mutational status. Taken to-
gether with the karyotypic studies,
these data positioned PTEN directly in
the RAS signaling network and con-
firmed the role of PTEN as one of the
key TSGs in melanoma.
PTEN is a TSG involved with regulat-
ing embryonic development, cell adhe-
sion, migration, apoptosis, stem cell
growth, and differentiation (Yamada
and Araki, 2001). At the molecular level,
Pten possesses many functions, including
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termination of PI3K signaling via
dephosphorylation of phospatidyl-
inositol-3,4,5-triphosphate to phospati-
dylinositol-4,5-biphosphate, upregulation
of cell-cycle arrest and proapoptotic
proteins, and downregulation of antia-
poptotic proteins in the Bcl-2 family. Pten
expression is lost or decreased in 15–50%
of melanomas even in the absence of
demonstrable mutations (Zhou et al.,
2000); thus, epigenetic silencing or hap-
lotype insufficiency is thought to play a
role in PTEN inactivation. The impor-
tance of PTEN in melanoma tumorigen-
esis is underscored by studies that suggest
that PTEN serves a critical role in PI3K
pathway activation in melanomas that
lack oncogenic NRAS mutations. Tsao
and others have shown that activation of
NRAS or loss of PTEN occur in a
reciprocal fashion and may be function-
ally equivalent with regard to their ability
to increase oncogenic signaling through
the PI3K pathway (Tsao et al., 2000).
Curtin et al. (2005) observed that tumor
specimens with BRAF mutations had
fewer copies of PTEN than specimens
with NRAS mutations, and that 82% of
the specimens with PTEN loss had
measurable increases in the expression
of phosphorylated Akt, thereby confirm-
ing PI3K pathway activation. Together,
these data have demonstrated that coac-
tivation of the MAPK and PI3K pathways
are important in melanoma tumorigen-
esis, and that PI3K activation frequently
occurs either via NRAS activation or
PTEN loss of function. Notably, akin to
NRAS and BRAF activation, PTEN loss
has been shown to lead to oncogene-
induced senescence in some tumor types
(Chen et al., 2005).
AKT. Akt is a downstream signaling
element in the Ras-PI3K pathway that is
responsible for phosphorylation and
regulation of multiple downstream ef-
fectors (reviewed in Manning and
Cantley, 2007). Akt activation is in-
itiated by growth factors or other
extracellular stimuli that activate PI3K.
Activated PI3K generates a lipid second
messenger, phosphatidylinositol-3,4,5-
trisphosphate, causing translocation of
Akt to the plasma membrane where it is
activated through phosphorylation.
Once activated, Akt has several differ-
ent enzymatic substrates, including
Mdm2, procaspase 9, NF-kB, mamma-
lian target of rapamycin (mTOR), and
p27, many of which contribute to
tumor proliferation and survival.
Evidence for Akt involvement in
melanoma comes from studies showing
(1) active phospho-Akt immunostaining
in 71.3% of primary melanomas and
71% of metastatic melanomas (Meier
et al., 2005; Slipicevic et al., 2005), (2)
increased Akt3 activity in melanoma
lines, and (3) induction of apoptosis
upon siRNA-mediated repression of
Akt3 (Stahl et al., 2004). It is worth
noting that no activating mutations of
Akt have been detected despite reports
of overexpression. More recently, ec-
topic expression of Akt was shown to
transform a nontumorigenic melanoma
cell line into one with a highly tumori-
genic phenotype, thereby suggesting
that Akt may serve as a molecular
switch that enhances aggressiveness
through tumor angiogenesis and the
generation of superoxides (Govindara-
jan et al., 2007). With regard to
resistance to apoptosis, Akt is known
to phosphorylate Creb, increase anti-
apoptotic Bcl-2, and inhibit apoptotic
Bad (del Peso et al., 1997). PRAS40 has
also been identified as a substrate of
the Akt3 kinase that regulates the
apoptotic sensitivity of melanoma cells
(Madhunapantula et al., 2007).
The CDKN2A/CDK4 network:
constraining tumor growth and
promoting senescence
There is no question that oncogenic
signaling through the NRAS network
plays a central role in the melanocytic
proliferation. However, the fact that
NRAS and BRAF activating mutations
are alone insufficient to lead to malig-
nant transformation, and that onco-
genic BRAF results in a senescence-
like state highlights the requirement for
cooperation of other pathways. Onco-
gene-induced senescence is thought to
primarily involve activation of tumor
suppressors such as p16INK4A, p14ARF,
RB, and TP53 (Mooi and Peeper, 2006).
Therefore, in order for malignant trans-
formation to occur, the mechanisms
that mediate senescence must be over-
ridden. As such, patients that possess
germline mutations in these genes have
increased susceptibility to melanoma.
CDKN2A. In 1988, Cowan et al. hy-
pothesized that discrete genetic changes
identified through karyotypic analyses
of cultured melanocytes from a variety
of lesions, including congenital nevi,
dysplastic nevi, and melanoma may
reveal critical information regarding
melanoma progression (Cowan et al.,
1988). Although all congenital nevi and
most dysplastic nevi (22/26) had normal
karyotypes, all melanomas exhibited
abnormal chromosomal panels. The
only chromosomal change common to
the dysplastic nevi with abnormal karyo-
types and melanomas was the loss of
one copy of chromosome 9 or its short
arm, 9p. These data were the first to
implicate deletion of a gene(s) on 9p as
an initial step in the malignant trans-
formation of melanocytes.
Subsequent deletional analyses loca-
lized regions of loss-of-heterozygosity on
chromosome 9p (Fountain et al., 1992)
with mutational analyses revealing dele-
terious changes in the CDKN2A gene in
a high percentage of cancer lines,
including melanoma (Kamb et al.,
1994). Melanoma cell lines frequently
exhibited loss of both CDKN2A copies
(that is, homozygous deletions); those
that retain at least one copy of CDKN2A
often carried nonsense, missense, or
frameshift mutations of the remaining
allele. In ensuing studies, germline
CDKN2A mutations were identified in
25–50% of familial melanoma kindreds
(Soufir et al., 1998) and in up to 10% of
individuals with multiple primary mela-
nomas; somatic CDKN2A alterations
have been reported in up to 30–70% of
sporadic melanomas (Bartkova et al.,
1996; Walker et al., 1998). These
collective findings defined CDKN2A as
the major TSG in melanoma.
The CDKN2A gene is unique in that it
encodes two proteins involved in mela-
noma growth and survival (Sharpless
et al., 2003; Figure 1): p16INK4A (cyclin-
dependent kinase (CDK) inhibitor 2a)
and p14ARF (alternative reading frame).
p16INK4A inhibits Cdk4/6-mediated
phosphorylation of the retinoblastoma
protein. In the hypophosphorylated
state, Rb binds and represses the E2F
transcription factor and prevents G1-to-
S transition. On the other hand, p14ARF
directly prevents Mdm2 from acceler-
ating the degradation of p53. Thus,
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loss of the CDKN2A locus negatively
impacts on both the Rb and p53 path-
ways. In addition to its effects on the
p53 pathway, there is emerging evi-
dence to suggest that p14ARF also
possesses tumor-suppressive effects
that are independent of p53. Ha et al.
(2007) recently used a mouse model to
demonstrate that p14ARF, and not p53,
suppressed early melanoma genesis
and operated independent of p53 to
induce melanocyte senescence. This
added benefit of ARF loss may help
explain why CDKN2A, as opposed to
p53, is preferentially abrogated in
melanoma.
CDKN2A appears to play a central
role in preventing cancer formation by
mediating a senescence-like state
upon oncogenic stress (Serrano et al.,
1997). Indeed, oncogenic mutations in
NRAS require concomitant loss of
CDKN2A in order to progress to frank
melanoma (Ackermann et al., 2005).
Interestingly, oncogenic BrafV600E-
induced senescence in melanocytes likely
involves additional regulators in addition
to CDKN2A (Michaloglou et al., 2005).
CDK4/CCND1. Given that p16INK4A
needs to directly interact with the
cyclin–Cdk complex in order to inhibit
its protein kinase activity, changes in
CDK4 that render it resistant to
p16INK4A mimic p16INK4A loss. In fact,
both somatic and germline mutations
in CDK4 have been detected in mela-
noma cell lines (Tsao et al., 1998a) and
melanoma families (Zuo et al., 1996),
respectively. All mutations in CDK4
reported to date fall in the p16INK4A
binding region (Lys22 or Arg24) and
prevent p16 from binding to and
inhibiting Cdk4. Bartkova et al. (1996)
elegantly demonstrated that a Cdk4R24C
melanoma cell line was resistant to p16
microinjection but was cell cycle ar-
rested with microinjection of cyclin
D1-neutralizing antibody.
CCND1 (cyclin D) is another crucial
component of the Cdk4/6 complex that
has long been recognized as an impor-
tant oncogene in a variety of other
cancers, including colon, lung, bladder,
head and neck, and breast cancers
(Alao, 2007). Oncogenic Ras has been
shown to positively impact the cell cycle
by upregulating cyclin D1 through
MAPK signaling (Filmus et al., 1994),
thereby serving as a link between the
MAPK and p16-cyclin D/CDK4-Rb path-
ways. Moreover, the oncogenic effects
of Ras in breast cancer are entirely
dependent on cyclin D1, and that mice
lacking cyclin D1 are resistant to breast
cancers induced by the Neu and Ras
oncogenes (Yu et al., 2001). Although
early studies of CCND1 in melanoma
failed to identify genetic alterations
(Maelandsmo et al., 1996), more recent
studies of a less common melanoma
subtype, acral lentiginous melanoma,
demonstrated frequent amplification of
the chromosomal region that encompass
the CCND1 locus (Bastian et al., 1998,
2000a). Sauter et al. (2002) compared
CCND1 gene copy number and protein
expression in 137 invasive primary
cutaneous melanomas (71 superficial
spreading, 17 nodular, 19 lentigo malig-
na, 18 acral lentiginous, and 12 unclas-
sifiable melanomas) and observed a high
frequency of CCND1 gene amplification
and protein overexpression in acral
lentiginous melanomas (44.4%); lower
rates of CCND1 amplification were
observed in the other melanoma sub-
types (11% for lentigo maligna, 6% for
superficial spreading melanoma). In a
pivotal functional test, they also showed
that antisense-mediated knockdown of
CCND1 caused apoptosis in vitro and
led to significant tumor shrinkage of
melanoma xenografts in mice, thus
confirming a role for CCND1 as a
melanoma oncogene. Within a pathway
context, amplifications of either CCND1
or CDK4 have been observed to occur in
a reciprocal fashion with known tumor-
promoting lesions in the MAPK path-
way, including activating mutations in
NRAS and BRAF (Curtin et al., 2005).
Additionally, CCND1 amplifications
were noted to occur more frequently
on melanomas that arose on skin with
chronic sun-induced damage, a subtype
that rarely possesses BRAF or NRAS
mutations (Curtin et al., 2005).
The BCL-2/TP53 network: conferring
resistance to apoptosis and chemotherapy
Although signaling networks that pro-
mote tumor proliferation or negotiate
senescence are undoubtedly important,
there has recently been increasing atten-
tion given to the downstream genetic
elements that underlie melanoma’s re-
sistance to apoptosis and chemotherapy.
Apoptosis is considered to be the primary
mechanism by which chemotherapeutic
agents result in tumor cell death (Igney
and Krammer, 2002); defects in this
process are considered one of the major
mechanisms by which highly chemo-
resistant tumors, such as melanoma,
defend themselves from the cytotoxic
effects of a wide variety of chemo-
therapeutic agents. Indeed, it has been
shown that defects within apoptotic
pathways, as well as aberrant modula-
tion by upstream signaling networks
(MAPK, PI3K, MITF, and others), con-
tribute to the inherent chemoresistance
observed in melanoma (Helmbach et al.,
2001; Soengas and Lowe, 2003; Zhang
et al., 2003; Madhunapantula et al.,
2007; McCubrey et al., 2007; Mhaidat
et al., 2007; Wang et al., 2007; Chetoui
et al., 2008).
Apoptosis occurs via two intercon-
nected pathways: the extrinsic (death
receptor) and intrinsic (mitochondrial-
dependent) pathways, both of which
ultimately lead to the activation of
effector caspases (caspases-3, -6, -7),
the final mediators of cell death
(Thornberry and Lazebnik, 1998). The
extrinsic pathway is triggered by death
receptors on the cell surface (for
example, TNF-R1, Fas/CD95, DR3,
TRAIL-R1, TRAIL-R2, and DR6), which
leads to recruitment of initiator cas-
pases (caspase-8 and -10), activation of
effector caspases, and subsequent cell
death (Scaffidi et al., 1998). Although
the extrinsic pathway has been impli-
cated in conferring chemoresistance
(Ashkenazi and Dixit, 1998; Fulda
et al., 2001), it is perhaps best known
for its key role in cellular immunity. In
melanoma, there are substantial data to
suggest that proper function of the
intrinsic pathway is required for che-
motherapy-induced tumor death, and
that dysregulation of this pathway is
largely responsible for melanoma’s
inherent chemoresistance (Borner
et al., 1999; Jansen et al., 2000;
Helmbach et al., 2001; Soengas et al.,
2001; Heere-Ress et al., 2002; Thallin-
ger et al., 2003; Galluzzi et al., 2006).
The intrinsic pathway becomes acti-
vated in response to a variety of
apoptogenic stimuli, such as growth
2580 Journal of Investigative Dermatology (2008), Volume 128
TL Hocker et al.
Melanoma Genetics and Therapeutic Approaches
factor deprivation, hypoxia, cell de-
tachment, and DNA damage (drug- or
environmentally induced; Igney and
Krammer, 2002; Danial and Kors-
meyer, 2004). These stimuli result in
the activation of the proapoptotic
members of the Bcl-2 superfamily,
leading to mitochondrial membrane
permeabilization and release of cyto-
chrome c, which forms a complex with
Apaf-1 and leads to the activation of
effector caspases that result in apopto-
sis. The other major signaling networks
in melanoma (for example, MAPK and
PI3K pathways) play a prominent role
in modulation of the intrinsic apoptotic
pathway (Eisenmann et al., 2003;
McCubrey et al., 2007; Wang et al.,
2007). Indeed, the prosurvival effects of
activated MAPK or PI3K signaling are
largely due to these pathways’ modula-
tion of the intrinsic apoptotic pathway.
A better understanding of the intrinsic
apoptotic pathway and the p53/Bcl-2
signaling network holds the promise of
helping to decipher some of the key
questions in melanoma, including me-
chanisms of chemoresistance and the
means by which to generate more
effective targeted therapies.
TP53. One of the major TSGs in all
human neoplasia, TP53 (p53), func-
tions to initiate DNA repair and/or
apoptosis when exposed to cellular
stresses, such as UV radiation.
Although TP53 mutations have been
associated with greater than 55% of all
human cancers (Greenblatt et al., 1994),
the incidence of TP53 mutations in
melanoma appears significantly less
common. Although estimates of TP53
mutational frequency have ranged in
the literature from 0 to 25%, a recently
constructed melanoma mutational da-
tabase demonstrated that the overall
mutational rate is closer to 13%
(Hocker and Tsao, 2007). Given the
high frequency of TP53 mutations in
most other human cancers, the relative
dearth of TP53 mutations in melanoma
suggests that functionally equivalent
genetic alterations occur elsewhere in
the p53 pathway. Indeed, mouse stu-
dies revealed reciprocity between
Trp53 and p19ARF in melanoma. Chin
et al. (1997) used a Tyr-v-HRAS;
Ink4a/ melanoma model to show
that wild-type p53 was retained in all
cases. These results complemented
those of a study that employed a
Tyr-v-HRAS; Trp53þ / model and
showed that the melanomas that arose
in this model possessed loss-of-hetero-
zygosity of the wild-type Trp53 allele
but retained p19ARF (Bardeesy et al.,
2001). In this report, not only was the
reciprocal relationship between Trp53
and p19ARF highlighted, but also was
the importance of the p53-Rb pathway
as an independent tumor-constraining
element in melanoma: reintroduction
of p16INK4A profoundly reduced the
growth of tumor cells that were null
for both Ink4a and ARF (Tyr-vHRAS
Ink4a/ tumor cells) but had no
effect on tumor cells derived from
Trp53-null melanomas. ARF has been
shown to directly interact with p53 as
well as inhibit Mdm2-mediated degra-
dation of p53, providing a molecular
basis to explain these findings (Kamijo
et al., 1998; Zhang et al., 1998). As
CDKN2A encodes both p14ARF and
p16INK4A, and is lost in B50% of
melanoma cases, it is reasonable to
speculate that the low mutational fre-
quency of TP53 in melanoma is due to
the frequent loss of CDKN2A, and more
specifically, its p14ARF product.
The mechanisms by which TP53may
act in humans remain to be fully
elucidated. In vitro studies of human
melanocytes null for p16INK4A, but with
wild-type p14ARF suggested that p53 was
capable of inducing a secondary form of
senescence that resembled that of fibro-
blasts (Bennett, 2003); however, it has
recently been shown that the presence
of ARF can result in melanocyte senes-
cence independent of TP53 (Ha et al.,
2007), so details regarding the role of
TP53 in senescence require further
elucidation. TP53 also has been sug-
gested to play a key role in apoptosis, as
evidenced by the fact that activated p53
induces the expression of multiple tran-
scriptional targets, including proapopto-
tic members of the Bcl-2 family such as
BAX, PUMA and NOXA (Henry et al.,
2002). Indeed, in many malignancies,
wild-type p53 function has been shown
to markedly enhance apoptosis after
contact with anticancer drugs in vitro
(Miyake et al., 1998). In 1998, Li et al.
compared the responses to chemo-
therapy (cisplatin or vincristine) of four
melanoma cell lines containing the
wild-type TP53 and four cell lines
carrying the mutant TP53 (Li et al.,
1998). Cisplatin killed nearly all cells in
the wild-type p53 cell lines, whereas up
to 95% of the cells in the mutant p53
cell lines survived (P¼ 0.005). Similarly,
after treatment with vincristine, 18% of
the wild-type p53 melanoma cells
survived compared with 55% of the
mutant TP53 cells (P¼ 0.04). A related
study demonstrated that melanoma cell
lines expressing wild-type TP53 have a
two- to threefold higher response to
anticancer agents than cell lines with
mutant TP53, and that this wild-type
cells had a corresponding decrease of
Bcl-2 (Li et al., 2000).
Bcl-2 family. The Bcl-2 network is
thought to be one of the most crucial
regulators of melanoma cell apoptosis
(Soengas and Lowe, 2003). At the core
of the Bcl-2 network lives a family of
anti- and proapoptotic proteins that
function to regulate and execute the
core mitochondrial pathway of apop-
tosis (reviewed in Danial and Kors-
meyer, 2004). Proper regulation
requires that a delicate balance be
maintained between proapoptotic
members of the Bcl-2 family (for
example, BAX, BAK, BAD, BID, Bim,
NOXA, PUMA) and the antiapoptotic
members (Bcl-2, Bcl-xL, Mcl-1, BCL-w,
and A1). The Bcl-2 family is divided
into three distinct groups—two proa-
poptotic and one antiapoptotic—based
on their conserved regions, which are
termed Bcl-2 homology (BH) domains.
The proapoptotic members come in
two varieties: ‘‘multidomain’’ members
that possess BH1-3 domains (BAX,
BAK), and ‘‘BH3-only’’ members
(BAD, BID, Bim, NOXA, PUMA). The
BH3-only members are upstream signal
detectors that become activated by a
variety of proapoptotic stimuli (Fig-
ure 1). Once activated, the BH3-only
members activate the multidomain
proapoptotic members, BAX and BAK,
which are ultimately responsible for
inducing mitochondrial permeabiliza-
tion, cytochrome c release, and apop-
tosis (Muchmore et al., 1996). The
antiapoptotic Bcl-2 family members
possess conserved BH1-3 domains,
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which come together to form a hydro-
phobic pocket that is capable of bind-
ing the BH3 domain of proapoptotic
members (Muchmore et al., 1996). It is
believed that the antiapoptotic mem-
bers primarily function by binding and
sequestering the BH3-only members
(Cheng et al., 2001). Indeed, many of
the signaling pathways responsible for
tumor growth and progression have
also been shown to possess profound
downstream effects on the regulation of
the Bcl-2 apoptotic network.
Antiapoptotic Bcl-2 members in
melanoma
Bcl-2, the founding member of the Bcl-2
family of proteins, was first identified at
the chromosomal breakpoint of
t(14;18) in follicular B-cell lymphoma
and found to block cell death following
a variety of toxic insults (Bakhshi et al.,
1985; Vaux et al., 1988). Bcl-2 has
been shown to serve a physiologic role
in the skin: in response to UV radiation,
keratinocytes secrete NGF, which
binds to melanocyte receptors and
leads to increased Bcl-2 expression
and resistance to apoptosis (Zhai
et al., 1996). In fact, high levels of
Bcl-2 expression have been found in
melanoma and melanocytes, providing
a likely explanation for the resistance of
melanocytes and melanoma to apopto-
sis induced by both physiological and
therapeutic triggers (Selzer et al., 1998;
Soengas and Lowe, 2003). Schmitt
et al. (2000) utilized retroviral gene
transfer of Bcl-2 to produce the multi-
drug resistance phenotype in primary
lymphomas in vivo, further supporting
a role for Bcl-2 in chemoresistance.
Aberrations in various signaling
pathways contribute to elevated Bcl-2
levels in melanoma. Oncogenic NRAS
has been shown to specifically upregu-
late the expression of Bcl-2 in vitro and
in SCID mice (Borner et al., 1999).
MITFmay also contribute to survival by
the transactivation of Bcl-2 (McGill
et al., 2002). Interestingly, although
some reports have suggested that ele-
vated levels of Bcl-2 are associated
with poor prognostic features such as
tumor ulceration and decreased patient
survival (Ilmonen et al., 2005), others
have found a decrease in Bcl-2 with
disease progression (van den Oord
et al., 1994; Tron et al., 1995). None-
theless, it has been shown that anti-
sense suppression of Bcl-2 or mutations
in MITF, a transcriptional regulator of
Bcl-2, leads to decreased melanoma
cell survival and increased sensitivity to
chemotherapy (Jansen et al., 1998;
Gautschi et al., 2001; McGill et al.,
2002); thus Bcl-2 has been considered
an attractive therapeutic target.
Given the mixed data regarding Bcl-2
expression and melanoma progression,
it has been proposed that alterations in
other members of the Bcl-2 family may
play a role in decreasing the depen-
dence on Bcl-2 for cell survival. In-
deed, other antiapoptotic members of
the Bcl-2 family, especially Mcl-1,
have emerged as potentially critical
melanoma survival genes. Mcl-1, an
atypical antiapoptotic Bcl-2 family
member, is highly expressed in primary
as well as advanced melanoma (Tang
et al., 1998). Multiple studies have
now demonstrated that resistance to
a variety of traditional and targeted
chemotherapeutic agents is largely
mediated by Mcl-1 overexpression
(Fernandez et al., 2005; Qin et al.,
2006; Verhaegen et al., 2006; Nguyen
et al., 2007; Wang et al., 2007; Wolter
et al., 2007; Chetoui et al., 2008). Mcl-
1 possesses qualities that distinguish it
from other antiapoptotic Bcl-2 mem-
bers. Whereas most antiapoptotic Bcl-2
members that show little selectivity in
their inhibition of proapoptotic mem-
bers BAK and BAX, Mcl-1 has been
shown to have a uniquely high speci-
ficity for suppressing apoptosis induced
by BAK but not BAX (Zhai et al., 2008).
In healthy cells, the Mcl-1 is believed
to be crucial in sequestering and
maintaining BAK in its inactive state
until the appropriate apoptotic signals
cause Mcl-1 to be eliminated, thereby
freeing BAK and allowing for apoptosis
to occur (Cuconati et al., 2003; Nijha-
wan et al., 2003). Mcl-1 also has the
unique property of rapid steady-state
turnover due to proteasomal degrada-
tion (Nijhawan et al., 2003); thus, in
the presence of chemotherapeutics that
inhibit proteasome function, such as
bortezomib, Mcl-1 can accumulate and
result in decreased sensitivity to these
agents (Nguyen et al., 2007). Lastly,
structural differences between Mcl-1
and other members in this class may
explain why ABT-737, a recently de-
scribed small molecule inhibitor of Bcl-
2/Bcl-xL, does not exhibit potency
against Mcl-1 (Oltersdorf et al., 2005).
Due to its implicated roles in melano-
ma as well as its unique structural and
functional properties, there is signifi-
cant interest in generating pharmaceu-
tical agents that target Mcl-1.
Proapoptotic Bcl-2 members in
melanoma
Although the multidomain proapopto-
tic members, BAX and BAK, are ulti-
mately responsible for inducing
mitochondrial permeabilization and
apoptosis, the proapoptotic BH3-only
members have been the focus of recent
attention, largely due to their apical
regulatory role in the death-signaling
cascades. Of the BH3-only members,
NOXA has emerged as a key molecule
due to its prominent role in BAK
activation. As mentioned previously,
Mcl-1 has a high specificity for binding
and sequestering BAK, thereby prevent-
ing it from initiating apoptosis. Like
BAK, NOXA possesses a BH3 domain
that has a high specificity for binding
with Mcl-1. When activated by various
stimuli, NOXA binds to Mcl-1, thereby
freeing BAK from the BAK–Mcl-1 com-
plex and promoting apoptosis (Willis
et al., 2005). Qin et al. (2005) recently
demonstrated that the chemotherapeu-
tic agent, bortezomib, was effective in
inducing cell death in human melano-
ma cells, but not normal proliferating
melanocytes. This agent’s efficacy was
shown to be due to p53-independent
induction of NOXA, as blockade with
an antisense oligonucleotide reduced
the apoptotic response by 30–50%.
APAF-1. Apaf-1 is a tumor suppressor
that may function as an important
downstream mediator of p53-induced
apoptosis. In 2001, Soengas et al. found
that aberrant methylation lead to loss of
Apaf-1 expression and rendered the
cells unable to execute the normal
apoptotic response following p53 acti-
vation (Soengas et al., 2001). Confirm-
ing a role for Apaf-1 as a tumor
suppressor, they found that restoration
of physiologic Apaf-1 levels by gene
transfer reversed chemoresistance and
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returned the cell’s ability to induce
apoptosis in response to p53 activation.
Notably, they also demonstrated that
administration of the demethylating
agent, 5-aza-2-deoxycytidine resulted
in a 20-fold increase in Apaf-1 expres-
sion, thereby restoring it to physiologic
levels and reversing the tumor’s resis-
tance to apoptosis. It has also been
reported that decreased levels of Apaf-
1 correlate with advanced disease and
chemoresistance (Mustika et al., 2005).
Melanocyte developmental pathways
Melanocytes are notably absent in the
leukodermic regions of both piebaldism
and Waardenburg syndrome. Germline
mutations in the receptor tyrosine ki-
nase, KIT, and microphthalmia tran-
scription factor (MITF) have been
described in piebaldism (Giebel and
Spritz, 1991) and Waardenburg Type
2A (Tassabehji et al., 1994), respec-
tively. As melanocyte homing to the
cutaneous surface requires a coordi-
nated balance of proliferation, migration
and survival, it stands to reason that
genetic factors, which promote these
processes may be usurped by melanoma
cells during tumorigenesis (Figure 2).
KIT. Multiple melanocytic signaling
pathways are initiated at the cell
membrane via activation of c-Kit, the
stem cell factor (SCF) receptor tyrosine
kinase that triggers many downstream
events, including activation of the
MAPK and PI3K pathways (Roskoski,
2005; Figures 1 and 2).
Although c-Kit has clear effects on
normal melanocytic proliferation, its role
in melanoma tumorigenesis has been
controversial. In 1992, Lassam et al.
reported that human melanoma cell lines
did not express detectable levels of KIT
mRNA or protein, in contrast to normal
melanocytes (Lassam and Bickford,
1992). Subsequent immunohistochem-
ical studies also found that c-Kit was
expressed in normal melanocytes, be-
nign nevi, and dysplastic nevi, but not
primary melanomas or metastases (Natali
et al., 1992; Montone et al., 1997).
Functional assays found that engagement
of c-Kit by SCF promoted proliferation of
normal melanocytes but inhibited pro-
liferation of melanoma cells (Zakut et al.,
1993; Huang et al., 1996). Early genetic
analyses also failed to implicate KIT as a
significant melanoma cancer gene. In
two related studies, a total of 3/153
human primary and metastatic melano-
ma samples demonstrated KIT mutations
(Willmore-Payne et al., 2005, 2006).
Notably, all three tumors demonstrated
an activating Leu576Pro mutation in
exon 11 of KIT and none of the three
had a mutation in BRAF, suggesting that
KIT may function as a rare independent
oncogene in melanoma.
The low prevalence of KITmutations
reported in consecutive cases of mela-
noma may in fact reflect a sampling
bias. Utilizing a combination of array
comparative genomic hybridization and
direct resequencing, Curtin and collea-
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Figure 2. Melanocyte developmental genes and melanoma. MITF and its many regulators are not only
key players in melanocytic development but are thought to also function as oncogenes in melanoma.
MITF dictates the pigment cell phenotype by regulating melanocyte-specific proteins (e.g., MART1) and
genes involved in melanoblast survival, lineage commitment, and melanocyte proliferation and survival.
MITF gene transcription and post-translational modifications are strongly influenced by multiple upstream
pathways, including c-Kit (purple), Wnt/b-Catenin (yellow), and a-MSH (blue). c-KIT (purple): Activation
of c-Kit, the stem cell factor (SCF) receptor tyrosine kinase, triggers many downstream events, including
activation of the MAPK and PI3K pathways and downstream modulation of MITF signaling. Wnt/b-
catenin (yellow): Activation of the Wnt/b-catenin pathway results in the stabilization and nuclear
translocation of b-catenin. Wnt stimulation activates Disheveled (DVL), which inhibits the axin-
adenomatous polyposis coli (APC)-glycogen synthase kinase-3b (GSK-3b) complex from phosphorylating
and thereby targeting b-catenin for proteosomal degradation. b-Catenin and the lymphoid enhancer-
binding factor (LEF, also known as TCF) transcription factor cooperate to induce MITF expression. a-MSH
(blue): a-MSH binds to the melanocortin 1 receptor (MC1R), resulting in the activation of adenylyl cyclase
(AC), cAMP production, and PKA activation. This results in the phosphorylation of CREB, which promotes
the recruitment of the CREB-binding protein (CBP) and subsequent MITF promoter activation.
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gues demonstrated KIT aberrations
(mutations, increased copy number or
amplification) in 39, 36, and 28% of
mucosal, acral, and chronically sun-
damaged melanomas. Strikingly, none
of the more common nonchronically
sun-damaged melanomas harbored KIT
mutations. As KIT alterations appear to
be associated with certain less com-
mon types of melanoma, it explains the
relatively low frequency of mutations
in unselected cases. Of the identified
KIT mutations, 11 fall within the juxta-
membrane region of the receptor tyr-
osine kinase (Curtin et al., 2006a).
Furthermore, immunohistochemical
studies showed that 79% of tumors
with mutations and 53% of tumors with
multiple copies of KIT demonstrated
increased c-Kit expression. Taken to-
gether, these data support a possible
role for KIT as both an oncogene and
therapeutic target in certain less com-
mon types of melanoma.
MITF. The MITF gene has emerged as a
master regulator of melanocyte devel-
opment (Figure 2). This transcription
factor dictates the pigment cell pheno-
type by regulating melanocyte-specific
proteins such as MART-1, enhances
and controls melanoblast survival, line-
age commitment, and melanocyte
proliferation and survival (Hodgkinson
et al., 1993; Widlund and Fisher, 2003;
Nishimura et al., 2005).
Mitf has multiple downstream ef-
fects, which together define numerous
aspects of normal pigment cell physiol-
ogy. Mitf directly promotes melanocyte
and possibly melanoma cell survival by
inducing the expression of the proto-
oncogene, Bcl-2, as one of its transcrip-
tional targets (McGill et al., 2002). Mitf
has also been shown to upregulate
TBX2, a suppressor of senescence
(Carreira et al., 2000). However, the
most direct evidence of MITF as a
‘‘lineage survival’’ melanoma onco-
gene emerged from an integrative
genomic approach. Garraway et al.
(2005) undertook a genome-wide view
of multiple cancer lines using high-
resolution single nucleotide poly-
morphism maps and high density gene
expression microarrays and found a
region on chromosome 3 that was both
amplified at the DNA level and over-
expressed at the RNA level in 10% of
primary melanomas and up to 20% in
metastatic melanomas. Furthermore,
ectopic expression of MITF along with
BRAFT1799A resulted in melanocyte
transformation, thereby substantiating
MITF as an oncogene in melanoma.
Despite the emerging view of MITF
in melanoma biology, critical questions
about its biology remain unanswered.
In contrast to its oncogenic behavior,
MITF has been shown to mediate G1
cell-cycle arrest by upregulating
p21Cip1 (Carreira et al., 2005). One
model posits that cell-cycle arrest and
differentiation takes place at high levels
of MITF expression whereas apoptosis
occurs at very low, or null, expression
levels (Gray-Schopfer et al., 2007);
thus, a tumor-favorable MITF level
may be required. Increases in MAPK
signaling leads to ubiquitin-dependent
proteolysis of MITF (Wu et al., 2000).
As complete loss of MITF is incompa-
tible with cell survival, melanoma
specimens with constitutively active
BRAF require mechanisms that main-
tain MITF levels in the range compa-
tible with tumorigenesis. MITF
amplification occurs in up to 20% of
melanomas and thus may account for
some of this MITF recovery; however,
the fact that only a small percentage of
melanomas with oncogenic BRAF and
NRAS possess MITF amplifications sug-
gests that other mechanisms are likely
involved. MITF is a downstream target
of b-catenin, a critical regulator of
melanoma cell growth (Widlund et al.,
2002); thus, an alternative mechanism
of MITF recovery could involve stabiliz-
ing mutations in b-catenin leading to
induction of MITF. Rubinfeld et al.
(1997) reported that 6/26 melanoma
cell lines possessed abnormal RNA
splicing or mutations in the b-catenin
gene (CTNNB1) that resulted in stabili-
zation of the protein. Subsequent studies
using primary melanoma specimens
demonstrated that nuclear accumula-
tion of b-catenin occurs in nearly one-
third of cases, although CTNNB1
stabilizing mutations are far less fre-
quently observed than was initially
reported for cell lines (Rimm et al.,
1999; Omholt et al., 2001). Given that
MITF plays a central role in melanocyte
and tumor survival, further delineation
of the genetic network that regulates,
and is regulated by, MITF is warranted.
b-Catenin. Like c-Kit and Mitf,
b-catenin has also been shown to be
critical in melanocyte lineage develop-
ment (Dorsky et al., 1998). b-Catenin is
a crucial downstream mediator of Wnt
pathway signaling (Figure 2). Thus,
melanomas often show constitutive
activation of the Wnt signaling as
revealed by nuclear accumulation of
b-catenin (Rimm et al., 1999). One
mechanism for Wnt pathway stimula-
tion is via oncogenic stabilization of
b-catenin (Rubinfeld et al., 1997). In a
recent model of murine melanoma,
Delmas et al. showed that melano-
cyte-specific overexpression an onco-
genic b-catenin (ST-A variants) allele
cooperated with oncogenic NRAS to
transform melanocytes in vivo (Delmas
et al., 2007). Functional analyses de-
monstrated that b-cateninSTA immor-
talized melanocytes by repressing
p16Ink4a expression, thereby bypassing
the need for CDKN2A deletion.
Other mutational targets
Without question, our understanding of
the genetic networks that drive melano-
ma proliferation, survival, and invasive-
ness has increased substantially in the
postgenomic era. The Sanger Center
maintains a catalog of all mutations
reported in cancer, and currently there
are over 600 genes which have been
shown to be mutated with at least one
alteration in melanoma. The number of
putative melanoma oncogenes and
TSGs continues to grow at a rapid pace.
As whole-genome sequencing becomes
more affordable and widely employed,
mutations will be discovered in pre-
viously unknown genetic targets; this is
likely to be true especially for rarer
melanoma subtypes (for example, mu-
cosal, acral, uveal) and other melano-
mas that have no mutations in currently
known oncogenes and TSGs.
With whole-genome sequencing
around the corner, the major challenge
in the coming years will rest in our
ability to discriminate between ‘‘dri-
ver’’ mutations—that is, those genetic
alterations that promote a certain
cancer phenotype—and ‘‘passenger’’
mutations—that is, those variants that
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occur at low frequency and have
uncertain phenotypic impact. One of
the major challenges of cancer geno-
mics is to integrate multiple complex
genome-wide datasets in order to
define biology beyond statistical signa-
tures. For example, Kim et al. (2006)
applied a comparative oncogenomics
paradigm to melanoma gene discovery.
These investigators characterized meta-
static murine melanoma variants on the
genomic level and identified a focal
amplification on mouse chromosome 13;
one of the genes in this region, Nedd9,
was overexpressed in the mouse mela-
nomas. Gains of the syntenic region
(human chromosome 6p25) were also
observed in human metastatic melano-
mas along with overexpression of
NEDD9. Functional studies showed
that Nedd9 enhanced invasion of nor-
mal and transformed melanocytes
in vitro and metastases in vivo, thereby
implicating this gene as another onco-
gene in melanoma. Approaches such as
integrative genomics and comparative
oncogenomics will likely accelerate
the pace of discovery in melanoma.
A second critical challenge is to
leverage the gains made in our genetic
understanding toward greater therapeu-
tic success. Efforts in developing tar-
geted melanoma therapies have not
only been promising from a therapeutic
standpoint but have also increased our
understanding of melanoma genetics.
TRANSLATIONAL GENETICS: FROM
MUTATIONAL TO THERAPEUTIC
TARGETS
Dacarbazine (DTIC)—which possesses
response rates as low as 10–13% and
complete responses in only 5%—has
remained the mainstay of single-agent
chemotherapy treatment for advanced
melanoma for over 20 years (Eigentler
et al., 2003). Nitrosoureas, platinum
analogs, vinca alkaloids, and the tax-
anes all have been shown to have only
modest activities against metastatic
melanoma. Temozolomide (TMZ) is a
newer oral alkylating agent that func-
tions like DTIC—methylation of the
O6-position in guanine—and possesses
excellent bioavailability and central
nervous system penetration. In a ran-
domized controlled trial, TMZ was
shown to have equivalent response
rates and survival as DTIC (Danson
et al., 2003). The superior central
nervous system penetration of TMZ
may prove useful in a subset of patients
with advanced melanoma: a recent
study of 52 patients with brain metas-
tases demonstrated that TMZ yielded
stabilization in 7/52 (13%) patients and
complete or partial responses in 6
patients (11%); DTIC had previously
been shown to be minimally active in
patients with brain metastases (Boogerd
et al., 2007). Although TMZ may
represent an incremental improvement
in the systemic treatment of melanoma,
there has been no significant prolonga-
tion in survival time.
The generally poor efficacy of all
current single-agent chemotherapeutic
approaches has prompted myriad
studies involving combination chemo-
therapy, biochemotherapy, and tumor-
specific immunologic therapies. Unfor-
tunately, over the past 20 years, there
have been no substantial benefits with
regard to median survival, and many of
the combination regimens have the
drawback of increased toxicity (Eigentler
et al., 2003; Gogas et al., 2007). Much
of melanoma’s resistance to traditional
chemotherapy is believed to arise
intrinsically, by virtue of potent growth
and cell survival-promoting genetic
alterations. Therefore, significant atten-
tion has recently been focused on devel-
oping previously unknown targeted
therapies that aim to selectively shut
down the genetic aberrations that fuel
this tumor’s oncogenic engine, as well as
agents that are capable of decreasing
this tumor’s inherent resistance to
chemotherapy.
Targeting growth signaling
Given the importance of the RAS
signaling network in promoting melano-
ma proliferation and survival, therapies
specifically aimed at this pathway are
ideal for many reasons. First, this net-
work is the most frequently altered in
melanomas: up to 90% of melanomas
possess oncogenic alterations in NRAS
or one of its downstream pathways.
Second, activation of the MAPK and
PI3K pathways has been shown to lead
to increased proliferation, cell survival,
and contributes to melanoma’s inherent
chemoresistance by disrupting the death
receptor-, mitochondrial-, and endoplas-
mic reticulum stress-induced apoptotic
pathways (Eisenmann et al., 2003;
Zhang et al., 2003; Hersey et al., 2006;
Jiang et al., 2007).
c-Kit. c-Kit is currently thought to be a
melanocyte lineage gene as well an
upstream regulator of Ras and the MAPK
and PI3K pathways (Figures 1 and 2). It
has gained attention recently due to the
observation that it likely serves as an
oncogene in a selected population of
melanoma subtypes that do not possess
the more common genetic alterations in
NRAS or BRAF that lead to activation of
the MAPK pathway.
Imatinib mesylate is a receptor tyr-
osine kinase inhibitor that inhibits BCR-
ABL, as well as c-Kit, and has been FDA
approved, given its efficacy in treating
chronic myelogenous leukemia and gas-
trointestinal stromal tumors (Gschwind
et al., 2004). At this time very few
responses have been noted in melano-
ma. One recent phase II trial showed no
objective clinical responses with signifi-
cant toxicity in 26 patients with meta-
static melanoma; however patients with
KIT-altered tumors were not specifically
enrolled. There was one patient found to
have strong KIT expression on immuno-
histochemistry with metastatic acral mel-
anoma who achieved a near complete
response for 1 year (Wyman et al., 2006).
As discussed previously, Curtin et al.
found KIT alterations in acral melanomas
and these recent genetic findings may
explain why there has been an observed
lack of response to imatinib in unse-
lected melanomas. Indeed, better patient
selection may improve response rates;
there is currently an ongoing trial testing
imatinib in patients with metastatic acral
and mucosal melanomas (ClinicalTrials.
gov Identifier: NCT00424515).
Nras. Given the sheer prevalence of
RAS mutations in human cancer, direct
and efficacious inhibition of oncogenic
Ras is an ideal therapeutic goal. Farne-
syltransferase inhibitors, such as tipi-
farnib and lonafarnib, block Ras
activation by inhibiting post-transla-
tional farnesylation thereby preventing
translocation of Ras to the plasma
membrane and subsequent Ras signal-
ing (Figure 1). To date, however, phase
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III trials involving these agents in
different cancers have been disappoint-
ing as monotherapy. As oncogenic
NRAS overexpression has been asso-
ciated with increased resistance to
cisplatin (Jansen et al., 1997), inhibi-
tion of Ras activity could also be
leveraged to reduce chemoresistance.
Preliminary data suggest that lonafar-
nib, together with cisplatin, may en-
hance melanoma apoptosis in vitro
(Smalley and Eisen, 2003; Morgillo
and Lee, 2006). ISIS 2503, an antisense
oligonucleotide that targets HRAS and
other farnesyl tranferase inhibitors may
be used as part of a combination
therapy regimen. Additionally, a recent
study by Stecca et al. (2007), demon-
strated that Sonic Hedgehog-GLI sig-
naling is necessary for the growth,
recurrence and metastasis of melanoma
xenografts in mice with activating
genetic mutations in the RAS signaling
network. Thus, future agents that sup-
press the function of SHH pathway
signaling may thus prove especially
useful in melanomas that are driven
by oncogenic NRAS.
Braf. As BRAF mutations occurs at such
high rate in melanomas, targeted ap-
proaches against BrafV600E represent an
ideal approach. Sorafenib (BAY 43-
9006) is a first generation nonselective
RAF inhibitor that has been shown to
abrogate MAPK signaling biochemi-
cally and to harbor antimelanoma
effects in vitro (Karasarides et al.,
2004). As sorafenib also targets vascu-
lar endothelial growth factor and plate-
let-derived growth factor receptors,
many of its antitumor effects are
thought to be caused by its antiangio-
genic activity (Sharma et al., 2005).
Sorafenib’s efficacy in renal cell carci-
noma—a tumor that lacks mutated
BRAF (Dorval et al., 1999)—further
supports the notion that sorafenib’s
activity extends beyond Braf inhibition.
Early clinical trials have failed to
show significant efficacy with sorafenib
as monotherapy in advanced melanoma
(Ahmad et al., 2004; Flaherty et al.,
2005; Eisen et al., 2006). Recent results
with sorafenib in combination with
carboplatin and paclitaxel have been
more promising. In one study, 19 of 35
(54%) patients with predominantly M1c
disease (all patients with visceral metas-
tases or any patient with an elevated
serum LDH above the upper limit of
normal regardless of disease site)
showed prolonged periods of stable
disease, with 11 (31%) experiencing
partial responses (Flaherty et al., 2004).
In another phase II trial in patients with
advanced melanoma, sorafenib in com-
bination with TMZ has also been well
tolerated and preliminary results have
shown that it may be effective in treating
patients with brain metastases, as well
as lead to increased tumor-cell apopto-
sis in vivo (Amaravadi et al., 2006). In a
two-stage uncontrolled phase II trial
studying sorafenib in combination with
DTIC, results of the first stage of the trial
have shown a median progression-free
survival at 3.6 months (versus 1.6
months for DTIC alone) and a partial
response rate of 16.7% (versus 7%;
Lorigan et al., 2006). Thus, this combi-
nation therapy compares favorably to
previous studies of DTIC monotherapy.
As MAPK activation is known to mod-
ulate the Bcl-2 network, it is tempting to
propose that the efficacy of combined
regimens (BRAF inhibitorþ traditional
chemotherapeutic agent) stems from
sorafenib’s indirect effects on the Bcl-
2 network. Unfortunately, these studies
did not assess for this effect.
Sorafenib’s efficacy may be im-
proved by combining it with other
targeted therapies. Sorafenib has re-
cently been shown to activate glycogen
synthase kinase-3b in melanoma cell
lines (Panka et al., 2008); activation of
this kinase correlates with increased
Bcl-2, Bcl-xL, and survivin expression
and decreased antitumor efficacy of
sorafenib. Therefore, sorafenib given in
conjunction with targeted therapies
against glycogen synthase kinase-3b
or the antiapoptotic Bcl-2 family mem-
bers may prove useful. Also, it was
shown that activated glycogen synthase
kinase-3b contributes to the decreased
the levels of the proapoptotic BH3-only
member, NOXA; agents that induce
NOXA expression may thus prove
valuable. These data emphasize the
link between oncogenic and Bcl-2
survival pathways and serve as a
poignant reminder that targeting of
only one genetic aspect of melanoma
will likely be insufficient.
Despite the mixed success achieved
thus far with sorafenib, there is tremen-
dous enthusiasm for other, more spe-
cific anti-Braf therapeutics. Currently,
more specific Braf inhibitors, RAF-265
(CHIR-265) and PLX-4032 (Plexikkon)
are in phase I study for stage III/IV
melanoma and advanced solid tumors,
respectively.
MEK. MEK inhibition is a prime target
for melanoma therapy given Braf’s
downstream dependence on MEK for
signal propagation. Recently, melano-
ma cell lines harboring BRAFmutations
were found to be markedly more
sensitive to MEK inhibition than lines
with NRAS mutations (Solit et al.,
2006). These findings suggest that
‘‘downstream’’ targeting could in fact
be a viable approach if the genetic
lesion itself is not susceptible to ther-
apeutic intervention. In preclinical stu-
dies, CI-1040, a small molecular
weight MEK inhibitor, was found to
completely suppress growth of BRAF-
mutant melanoma xenografts with
regression of pulmonary metastases
and prevention of new pulmonary
metastases (Collisson et al., 2003). In
a phase I study of 66 patients with
various advanced malignancies, CI-
1040 was found to be relatively safe
and modestly effective: 1 individual
experienced a partial response whereas
19 patients had stabilization of their
disease (Lorusso et al., 2005b).
PD0325901, a second generation Mek
inhibitor, is 100 times more potent and
is490-fold more potent in suppressing
pERK relative to CI-1040. A recent
phase I/II trial of PD0325901 enrolled
27 patients and demonstrated partial
responses in 2/27 and stable disease in
5/27 (Lorusso et al., 2005a). Signifi-
cantly, tumors from partial responders
showed substantial ERK inhibition—a
critical component of the targeted
mechanism. In future studies of
PD0325901, stratification of study pa-
tients according to BRAF mutational
status may prove beneficial. Another
compound that acts similarly to
PD0325901, ARRY-142886 (AZD6244),
has been shown in a mouse xenograft
model to decrease pERK and suppress
tumor growth in a cytostatic fashion
(Haass et al., 2008); coadministration
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of AZD6244 and docetaxel was cyto-
toxic and resulted in tumor regression.
This agent is currently being tested in
phase II clinical trials (ClinicalTrials.-
gov Identifier: NCT00338130). Lastly,
anthrax lethal toxin has been shown to
selectively degrade MEK1 and MEK2
and induce regression of human mela-
noma xenografts, thus clinical trials are
currently underway (Koo et al., 2002).
Notably, it has been shown that Mek
inhibitors achieve much of their apop-
totic effect through suppression of the
antiapoptotic Bcl-2 member, Mcl-1,
and that melanoma lines that are
resistant to MEK inhibitors do not
display Mcl-1 suppression in response
to MEK inhibitors (Wang et al., 2007).
This finding may explain the ability
of MEK inhibitors to increase tumor
sensitivity to traditional chemo-
therapeutic agents and has implications
for designing optimal combination
regimens. Thus, as is the case with
other genes in the MAPK pathway, a
better understanding of the crosstalk
that occurs with the Bcl-2 apoptotic
network will likely be crucial in the
development of rational treatment regi-
mens involving MEK inhibitors (dis-
cussed in more detail later).
Downstream targets in the PI3K pathway
The PI3K/Akt3 signaling pathway is
aberrantly activated in up to 70% of
melanomas and has been implicated in
tumor progression and chemoresistance
(Kim et al., 2005). Reduction of signaling
through this pathway using small inter-
fering RNA (siRNA) against AKT3 or by
expressing Pten protein has been shown
to reduce tumor-cell survival by increas-
ing apoptosis (Stahl et al., 2004).
Although direct targeting of Akt3 has
the potential of being an effective
therapeutic approach in melanoma, the
ATP-binding regions are highly con-
served between the three isoforms of
Akt (Akt1, Akt2, Akt3) thus making it
difficult to specifically inhibit Akt3 with-
out also inhibiting the other isoforms and
enduring the resulting toxicity (Kumar
et al., 2001). Thus, one approach that
has been employed is to target direct
substrates of Akt3, such as mTOR. In
fact, of the drugs currently being tested
in PI3K pathway inhibition, mTOR
inhibitors, CCI-779 (Temsirolimus) and
RAD001 (Everolimus), are the most
advanced (Dancey, 2006). mTOR acts
downstream of Akt to modulate protein
synthesis, cell-cycle progression, and
angiogenesis. In a phase II trial of 33
patients with metastatic melanoma,
monotherapy with CCI-779 showed
one partial response lasting 2 months
and a median time-to-disease progres-
sion of 10 weeks (Margolin et al., 2005).
More promising results were seen in
interim analysis of a recent two-stage
phase II trial using RAD001 as mono-
therapy in patients with stage IV mela-
noma. Of the 20 patients studied, 35%
experienced stable disease at 16 weeks
(Rao et al., 2006).
Another direct substrate of Akt,
PRAS40, has recently been identified
as a substrate of the Akt3 kinase that
regulates the apoptotic sensitivity
of melanoma cells (Madhunapantula
et al., 2007). Targeting of PRAS40 or its
upstream regulators inhibited tumor
development in mice and increased
the sensitivity of melanoma cells
to apoptosis-inducing agents. Unfortu-
nately, like mTOR, PRAS40 is a cyto-
solic protein expressed by all tissues,
and therefore inhibitors would not be
expected to possess high specificity in
targeting melanoma tumor cells.
Recently, Tsao et al. (2004b) found
genetic evidence for cooperativity be-
tween BRAF mutagenesis (that is,
MAPK signal stimulation) and PTEN
mutagenesis (that is, PI3K signal stimu-
lation). These findings suggest that
parallel inhibition of targets in both
MAPK and PI3K pathways may be
synergistic in effect. A phase I/II study
is currently underway testing CCI-779
in combination with sorafenib in stage
III/IV melanoma (ClinicalTrials.gov
Identifier: NCT00349206).
Restoring tumor suppressor function
Restoring function of a lost or defective
gene in cancer has generally proven to
be more difficult than blocking a hyper-
functional gene; thus it is not surprising
that most efforts in targeted melanoma
therapy have centered on suppression
of oncogene signaling rather than tumor
suppressor restoration. In recent years,
however, it has become appreciated
that the loss of many TSGs in melano-
ma—including PTEN, CDKN2A and
APAF-1—may not be permanent, but
instead arise via reversible alterations in
gene expression (that is, epigenetic
alterations). Epigenetic alterations in-
clude both DNA modifications (methy-
lation of CpG islands), and alterations
in DNA packaging. Over the past 5
years, more than 50 genes in melanoma
have been shown to be dysregulated
through epigenetic changes (Rothhammer
and Bosserhoff, 2007). Notably, hyper-
methylation of the CDKN2A promoter
region has been shown to lead to loss of
p16 expression in 19% of primary and
33% metastatic melanomas (Straume
et al., 2002). Similarly, PTEN has been
identified as a likely target for epige-
netic silencing, because its expression is
lost or decreased in up to 50% of
melanomas, even in the absence of
demonstrable mutations (Zhou et al.,
2000). Given the importance of these
and other tumor suppressors in mela-
noma, agents that have the ability to
reverse epigenetic silencing would be
an invaluable addition to our emerging
arsenal of targeted therapeutics against
melanoma.
DNA methylation is one of two
known mechanisms by which epige-
netic silencing occurs. Methylation is
mediated by DNA methyltransferases
(DNMTs), which are responsible for the
formation of a covalent attachment of a
methyl group to cytosine residues in
CpG dinucleotides. Although CpG-rich
sequences (CpG islands) are infrequent
in the genome, they are very common
in promoter regions of genes, being
found in nearly 50% of human genes
(Bird, 2002). Aberrant hypermethyla-
tion of the promoter regions of TSGs
can lead to gene silencing and thus
promote tumorigenesis. As the promo-
ter must be remethylated during each
cycle of DNA replication (Herman and
Baylin, 2003), DNMT inhibitors can be
used to target this type of epigenetic
silencing. Of the DNMT inhibitors,
5-azacytidine, 5-aza-20-deoxycytidine
(decitabine), fazarabine, and dihydro-
5-azacytidine have been the most
extensively studied. These agents are
phosphorylated and are incorporated
into DNA, then become covalently
linked to DNMT, thereby preventing
methylation. DNMT inhibitors have
shown some promise in melanoma. In
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2001, Soengas et al. (2001) found that
aberrant methylation lead to decreased
levels of Apaf-1, which correlated with
advanced disease and chemoresis-
tance. Using the DNMT inhibitor dec-
itabine, they were able to restore
Apaf-1 levels, apoptosome function
and chemosensitivity, thus serving as a
proof-of-principle for DNMT inhibitors.
DNMT inhibitors may also play a
role in the extrinsic apoptotic pathway
by reversal of the epigenetic silencing
of cytokine and IFN signaling path-
ways. In tumor cells and lymphocytes,
aberrant methylation influences the
expression of critical proteins in the
innate and acquired immune systems,
leading to resistance to apoptosis from
endogenous and exogenous (biochemo-
therapy) immunostimulatory molecules
(Reiner, 2005). Indeed, methylation of
IFN-stimulated genes has been pro-
posed to increase resistance to IFN-
mediated antiproliferative effects and
apoptosis (Kulaeva et al., 2003; Reu
et al., 2006). Recently, Reu et al. (2006)
demonstrated that decitabine signifi-
cantly augmented the antiproliferative
effects of IFN- a2 and IFN-b in cell
lines, leading to a greater than 10-fold
increase in IFN-stimulated gene expres-
sion. They then used a nude mouse
xenograft model to assess the relative
efficacy of single-agent decitabine,
IFN-b, or the combination of the two,
and found that the combination treat-
ment resulted in greater growth sup-
pression (Po0.05) compared to either
agent alone. Similarly, it was recently
demonstrated that decitabine leads to
demethylation of DR4, a key receptor
in the Apo2L/TRAIL apoptotic pathway,
and was effective in restoring the
sensitivity of melanoma cell lines to
IFN-induced apoptosis (Bae et al.,
2008). Currently, phase I studies are
being conducted, studying the efficacy
of 5-azacytidine with IFN-a in patients
with metastatic melanoma (Clinical-
Trials.gov Identifiers: NCT00398450,
NCT00217542). One recent phase I
study used sequential low dose decita-
bine with high-dose IL-2 to evaluate if
the addition of this demethylating agent
could decrease the toxicity in melano-
ma and renal cell carcinoma patients.
Although decitabine did not decrease
the toxicity of IL-2, objective responses
were seen in 31% of melanoma
patients (Gollob et al., 2006).
Many histone deacetylase inhibitors
have been evaluated in melanoma and
some have shown promise in restoring
tumor suppressor function (reviewed in
Boyle et al., 2005). One interesting
agent is valproate, a commonly used
agent in the treatment of epilepsy,
mood stabilization, and migraine head-
aches that has also been shown to be
an effective histone deacetylase inhibi-
tor (Blaheta et al., 2002). Recently,
Valentini et al. (2007) assessed the
effect of valproate on melanoma cell
lines. Using a cell line with known
knockdown of p16 expression, they
found that valproate administration
led to a fourfold increase in p16,
apoptosis in 50% of tumor cells, and
resulted in an accumulation of tumor
cells that were blocked in the G1/G0
phase (87% after 72 hours). They also
noted that upon p16 re-expression
many of the cells assumed a senes-
cence-like phenotype; this is significant
because oncogene-induced senescence
is essentially irreversible (Mooi and
Peeper, 2006), and thus may mark a
shift in behavior toward that of a
benign nevus. Significantly, valproate
sensitized resistant melanoma cell lines
to cisplatin and etoposide-mediated
apoptosis in a synergistic fashion,
suggesting that histone deacetylase
inhibitors may be useful as part of a
combined regimen with traditional
chemotherapeutic agents.
One of the drawbacks of DNMT and
histone deacetylase inhibitors is their
lack of tumor-cell specificity. Design of
tumor-specific inhibitors or targeted
delivery to tumor cells may prove
useful in increasing the utility of these
agents. Nonetheless, the potential of
these agents to restore normal tumor
suppressor function mandates further
investigation.
Targeting genetic elements that confer
resistance to apoptosis and chemotherapy
As discussed previously, defects in
apoptosis are thought to be one of the
major mechanisms by which melanoma
is thought to resist the cytotoxic effects of
chemotherapeutic agents. Alterations
within the intrinsic apoptotic path-
way—both primary as well as secondary
defects due to aberrant upstream signal-
ing (MAPK, PI3K, and p53 pathways)—
are thought to be major contributors to
the inherent chemoresistance observed
in melanoma (Helmbach et al., 2001;
Soengas and Lowe, 2003). Thus, ther-
apeutic agents that target the down-
stream mediators of apoptosis have
recently received much attention.
Bcl-2. Experimental data have shown
that antisense suppression of Bcl-2 lead
to decreased melanoma cell survival
and increased sensitivity to chemother-
apy. Oblimersen, an 18-base antisense
oligonucleotide that mediates cleavage
of Bcl-2 mRNA, is able to suppress
Bcl-2 and has yielded modest results in
humans. A large multinational rando-
mized control trial that compared DTIC
plus Oblimersen to DTIC alone in 771
patients with advanced melanoma found
that the combination therapy resulted in
a higher objective response rate, durable
response rate, increased median progres-
sion-free survival, and a trend toward
increased overall survival (Bedikian
et al., 2006). Notably, 11 patients
(2.8%) in the combination group
achieved a complete response com-
pared with 3 patients (0.08%) in the
DTIC group; of the 11 who achieved a
complete response in the combination
group, 4 were disease-free for more than
36 months, whereas the 3 patients in the
DTIC group died at 20, 28, and 29
months. Additionally, incidence of se-
vere neutropenia and thrombocytopenia
was substantially lower in the combina-
tion group compared to current regi-
mens used to treat patients with
advanced melanoma.
Bcl-2 expression has been reported
to be high in early melanocytic lesions
but strongly decreased in advanced
melanoma (van den Oord et al.,
1994; Tron et al., 1995), suggesting
that other antiapoptotic Bcl-2 members
may serve as a substitute for Bcl-2 once
it is lost. Bcl-xL is thought to serve
many of the same functions as Bcl-2
and its expression is high in advanced
melanoma (Tron et al., 1995). Tumor
cells are able to switch expression from
Bcl-2 to Bcl-xL (Han et al., 1996),
and in many cases Bcl-2 and Bcl-xL
are expressed in a reciprocal fashion
(Arriola et al., 1999). Studies employing
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Bcl-xL antisense oligonucleotides
(Heere-Ress et al., 2002) and a bispe-
cific Bcl-2/Bcl-xL antisense oligonu-
cleotide have been performed, and
shown to induce apoptosis in up to
two-third of melanoma cells (Gautschi
et al., 2001; Del Bufalo et al., 2003).
Recently, encouraging in vivo results
were obtained with agents that simul-
taneously target Bcl-xL other antiapop-
totic Bcl-2 family members, such as the
small molecule inhibitors Obatoclax
and ()gossypol (Nguyen et al., 2007;
Wolter et al., 2007). Taken together,
these data support a role for Bcl-2 and
Bcl-xL inhibition in the treatment of
advanced melanoma.
Mcl-1. Mcl-1 is an antiapoptotic Bcl-2
family member that possesses many
unique qualities that make it an attractive
therapeutic target, including strong gene
expression at all stages of disease (Tang
et al., 1998; Leiter et al., 2000), highly
selective BAK inhibition (Zhai et al.,
2008), accumulation in response to
chemotherapeutic proteasome inhibition
(Nguyen et al., 2007), and lastly, struc-
tural differences between it and other
Bcl-2 members (Oltersdorf et al., 2005).
Preclinical studies of Mcl-1 inhibi-
tors have been encouraging. Thallinger
et al. (2003) used a SCID mouse model
to demonstrate that DTIC plus anti-
sense oligonucleotide against Mcl-1
resulted in a twofold increase in
tumor-cell apoptosis and significantly
reduced the mean tumor weight, com-
pared to DTIC alone. Notably, how-
ever, monotherapy with antisense
oligonucleotide against Mcl-1 was no
better than saline control, thus indicat-
ing a primary role for Mcl-1 in mod-
ulating chemosensitivity. Wang et al.
(2007) recently demonstrated that MEK
inhibitors achieve much of their apop-
totic effect through Mcl-1 suppression;
conversely, when melanoma cell lines
that are resistant to a selective MEK
inhibitor (U0126) are treated with
siRNA against Mcl-1, U0126-induced
apoptosis is substantially increased.
Similarly, Verhaegen et al. (2006)
demonstrated that TW-37, a rationally
designed small molecule against Mcl-
1, possesses synergistic tumor cell kill-
ing in the presence of MEK inhibitors.
These data suggest that Mcl-1 inhibitors
may prove useful when used in con-
junction with traditional chemothera-
peutic agents and/or MEK inhibitors.
Additionally, Chetoui et al. (2008)
demonstrated that siRNA against
Mcl-1 sensitizes melanoma cells to
Fas-induced apoptosis, raising the
possibility that Mcl-1 inhibition may
find use as part of a combined regimen
with immunotherapy.
Although Mcl-1 inhibitors may gen-
erally increase tumor-cell sensitivity to a
variety of traditional chemotherapeutic
agents, their unique relationship with
the proteasome inhibitor class of che-
motherapeutic agents may prove espe-
cially beneficial. Mcl-1 is a protein that
normally undergoes proteasomal degra-
dation, but in response to treatment
with proteasome-inhibiting agents such
as bortezomib, Mcl-1 levels increase
(Fernandez et al., 2005). Mcl-1 is a
potent antiapoptotic member of the Bcl-
2 family, and thus its accumulation may
account for the disappointing results
observed in a recent phase II trial of
single-agent bortezomib (Markovic
et al., 2005). A number of prior studies
had shown that a bortezomib induces
the expression Mcl-1’s proapoptotic
binding partner, NOXA, which is re-
sponsible for apoptosis (Fernandez
et al., 2005; Qin et al., 2005). Since
bortezomib simultaneously induces the
proapoptotic Bcl-2 member, NOXA,
and antiapoptotic Mcl-1, Mcl-1 inhibi-
tion is an attractive means for increasing
the efficacy of bortezomib. Qin et al.
(2006) demonstrated that knockdown of
Mcl-1 by a number of methods (siRNA,
UV light, fludaribine) potentiated borte-
zomib-induced apoptosis. siRNA direc-
ted against Mcl-1 led to a nearly
twofold increase in tumor-cell apoptosis
compared to bortezomib alone. A more
recent study demonstrated that Obato-
clax, a potent small molecule inhibitor
of Mcl-1, has single agent antitumor
efficacy and can synergize with borte-
zomib, even in the absence of NOXA
induction (Nguyen et al., 2007). Oba-
toclax is currently being tested as both a
single agent and as part of combination
regimens in over 10 phase Ib and phase
II clinical trials of leukemia, lymphoma,
and solid tumor malignancies. Wolter
et al. (2007) recently investigated the
mechanism and in vivo efficacy of
another agent, ()gossypol, an inhibitor
of Mcl-1/Bcl-2/Bcl-xL that is currently
being tested in phase II trials for other
malignancies. Strikingly, they reported a
significant decrease in metastases and
an increase in overall survival with
combined treatment; by day 17 of
treatment, more than 70% of control
mice had either died or were moribund
as a result of significant respiratory
complications. In contrast, no deaths
or significant discomfort was observed
in the ()gossypolþ bortezomib com-
bination group. Moreover, the average
number of lung metastases per mouse
was 50, 16, and 20 in animals treated
with placebo, single-agent bortezomib,
or single-agent ()gossypol, respec-
tively; in stark contrast, combination
therapy with ()gossypolþ bortezomib
resulted in an average of only three lung
metastases (P¼0.001). Given that
()gossypol has already been shown to
have a reasonable safety profile in
phase I studies of other malignancies,
combination ()gossypolþ bortezomib
may represent a possible strategy in
melanoma.
Proapoptotic Bcl-2 family members
As mentioned above, NOXA expres-
sion has been shown to be induced by
bortezomib (Qin et al., 2005, 2006). In
an elegant series of experiments, Niki-
forov et al. (2007) revealed that borte-
zomib led to increased c-Myc protein
function, and that NOXA expression
was only increased when c-Myc is
bound to its recognition sites in the
NOXA promoter. Transduction of c-
Myc into normal melanocytes, which
are resistant to bortezomib, resulted in
NOXA expression and newfound che-
mosensitivity to bortezomib. Similarly,
transduction of ectopic c-Myc into
melanoma cells led to increased re-
sponse to lower doses of bortezomib,
and enhanced the extent of cell death
twofold. The authors proposed that
agents that induce the expression of
NOXA and other apoptotic Bcl-2
family members might be clinically
useful. The small molecule, g-secretase
inhibitor, has been shown to be cap-
able of inducing NOXA expression in
melanoma but not melanocytes, and
thus may find use as a NOXA stimulant
(Nickoloff et al., 2005).
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Combinatorial approaches to targeted
therapy
Although numerous targeted therapies
have demonstrated promising preclinical
results, clinical trials using single-agent
targeted therapy have yet to demonstrate
any substantial benefit with regard to
survival. These disappointing results are
most likely due to the high degree of
crosstalk that occurs between each of
the melanoma signaling pathways—
growth promoting, growth restraining,
and apoptotic. Therefore, it has been
suggested that coordinated blockade of
multiple pathways may lead to im-
proved treatment efficacy.
One approach has been to employ
single agents that simultaneously act on
multiple melanoma signaling networks.
Benzoquinone anisomycin 17AAG is
one example of such an agent, and
achieves its multiple effects through
inhibition of heat-shock protein 90
(Hsp90). Hsp90 regulates protein fold-
ing, stability, activation, and proteo-
lysis in several important proteins;
inhibition of Hsp90 leads to proteoso-
mal degradation of chaperoned pro-
teins, including Braf, Cdk4, Cdk6, and
Akt. Thus, through Hsp90 inhibition,
17AAG targets multiple pathways si-
multaneously in melanoma cells. On-
cogenic Braf has been shown to be
more sensitive to 17AAG activity than
wild-type BRAF; however, because
17AAG also impacts other downstream
effectors of RAS, BRAF mutational
status alone does not predict melanoma
sensitivity to inhibition by this agent (da
Rocha Dias et al., 2005; Grbovic et al.,
2006). Two patients with melanoma
have experienced prolonged stabiliza-
tion of disease (Banerji et al., 2005) but
significant toxicity limits this agent’s
use. A second agent, the proteasomal
inhibitor, bortezomib (Velcade), has
been proposed to have effects on both
the Bcl-2 family and NF-kB (Amiri
et al., 2004) and thus may sensitize
melanoma cells to apoptosis through
multiple mechanisms. Indeed, bortezo-
mib has been shown to increase tumor
sensitivity to TMZ-induced apoptosis
in vitro and in vivo (Cusack et al.,
2001; Sunwoo et al., 2001). Although a
phase II trial of bortezomib revealed a
lack of efficacy as a single agent
(Markovic et al., 2005), this agent
may prove beneficial when combined
with other agents.
A second, more rational, approach
toward overcoming pathway crosstalk
involves the coordinated use of multiple
targeted agents. This approach seems
promising. In a recent combination
trial, Molhoek et al. compared the
in vitro efficacy of single-agent sorafe-
nib, single-agent rapamycin, and com-
bined therapy with sorafenibþ low-
dose rapamycin. They found that
combination therapy synergistically in-
hibited melanoma cell proliferation,
regardless of BRAF mutational status
(Molhoek et al., 2005), thus serving as
proof of principle for this approach.
Other studies have exploited our in-
creasing understanding of melanoma
drug resistance in order to rationally
select drug combinations that may
have synergistic effects. A prime ex-
ample of this approach involves the
coordinated use of MAPK pathway
inhibitors and Bcl-2 pathway modula-
tors. It is now appreciated that one of
the major mechanisms by which MAPK
pathway inhibitors induce apoptosis in
melanoma is through upregulation of
proapoptotic family members (includ-
ing PUMA and Bim) and downregula-
tion of antiapoptotic ones such as
Mcl-1 (and to a lesser extent, Bcl-xL
and Bcl-2; Eisenmann et al., 2003;
Wang et al., 2007; Panka et al.,
2008). As previously discussed, Wang
et al. (2007) exploited this fact by
showing that tumor-cell resistance to
U0126, a selective MEK inhibitor,
could be reversed with siRNA against
Mcl-1, leading to tumor cell death.
Another recent study demonstrated that
coadministration of U0126 and TW-37,
a potent small molecule inhibitor of
Mcl-1, results in synergistic tumor cell
killing (Verhaegen et al., 2006). To-
gether, these data suggest that the
concomitant use of MEK inhibitors
and agents that modulate the Bcl-2
family members may lead to synergistic
antitumor effects. Thus, investigation
into the rational pairing of multiple
targeted agents is warranted.
Future directions in targeted therapy
Although targeted therapies have not yet
led to substantial survival benefits in
advanced melanoma, we have learned
much from their successes and failures.
Due to tumor resistance to MEK inhibi-
tors, we now have an increased under-
standing of the genetic underpinnings of
melanoma’s inherent chemoresistance;
this insight has opened new doors with
regard to treatment. Among the many
opportunities for future investigation into
targeted melanoma therapy, some of the
more promising ones include: develop-
ment of more specific/potent single-
agents; coadministration of Bcl-2 family
modulators with traditional chemother-
apeutics, including bortezomib; coordi-
nated use of immunotherapies, MEK
inhibitors and targeted modulators of
the Bcl-2 family; biochemotherapy
coupled with DNMT inhibitors to restore
function of cytokine and IFN signaling
pathways; development of inhibitors of
the drug efflux pump ABCB5 (Frank
et al., 2005; Schatton et al., 2008),
which may be useful as single agents or
in conjunction with traditional chemo-
therapy or targeted agents.
CONCLUSION
Our understanding of the genetic under-
pinnings of melanoma has increased
vastly since 1984, when the first mela-
noma oncogene, NRAS, was discov-
ered. The genetic pathways and
alterations are now better defined in
the most common forms of cutaneous
melanoma. Although early experiences
with single-agent targeted therapies
have been somewhat disappointing,
they have also been instructive, leading
to further understanding of the crosstalk
between melanoma pathways and
opening doors for more promising
targeted regimens. Currently, it appears
that effective treatment of melanoma is
less likely to be achieved with one
‘‘magic bullet’’ than a coordinated
therapeutic attack on the elements that
underlie this tumor’s propensity for
growth and chemoresistance. A number
of combination regimens with second
generation targeted agents and tradi-
tional chemotherapeutics are now being
tested in clinical trials; we eagerly await
the results of these studies.
Although many of the newer ap-
proaches to targeted/combined therapy
are very promising for metastatic mel-
anoma in general, it is now clear that
melanoma is not a singular, homoge-
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nous disease entity with a common set
of genetic alterations. As the genetic
defects involved in various forms of
melanoma—such as uveal, mucosal
and leptomeningeal melanomas—har-
bor distinct activating pathways (Curtin
et al., 2005, 2006a; Hocker and Tsao,
2007), therapies that are designed to
target the genetic alterations observed
in the most common types of cutaneous
melanomas may not be beneficial in
the treatment other subtypes of mela-
noma; further studies will be required
to determine the genetic underpinnings
of these rarer forms of melanoma.
Another challenge will be to arrive
at a molecular classification of mela-
noma based on genetic and epigenetic
signatures. Currently, Breslow depth
and ulceration status remain the most
widely accepted prognostic factors
(Balch et al., 2001). There are no
commercially available laboratory tests
that accurately predict which early
stage tumors have a higher likelihood
of progression and therefore a worse
prognosis. Thus, identification of mo-
lecular signatures of melanoma pro-
gression would represent a major step
toward accurate survival counseling
and may aid in the identification and
administration of previously unknown
therapeutic targets. Despite these re-
maining challenges, it is without ques-
tion that we have come a long way in
our understanding of, and therapeutic
approaches to, this disease.
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